AbbVie

Activities: Pharmaceutical

Trending Articles

  1. Beneo presents its taste-boosting excipient, galenIQ at CPHI 2024 galenIQ is designed to improve the flavour of oral solid dosage (OSD) forms for more patient-centric pharmaceuticals
  2. Merck's MilliporeSigma cuts the ribbon on €290m US biosafety and analytical facility The site will host biosafety testing, analytical development and cell banking manufacturing services
  3. Seppic launches surfactant excipient for the optimisation of biological formulations The ingredient is compatible with sensitive biologics, and aims to stabilise injectables for improved bioavailability, efficacy and shelf life
  4. Strides Group launches CDMO OneSource Specialty Pharma at CPHI Milan The newly integrated CDMO primarily specialises in the manufacture of biologics, drug-device combos and gelatin capsules
  5. Johnson & Johnson completes V-Wave acquisition to support patients with heart failure The strategic acquisition will bolster the pharma giant's MedTech offerings for patients with cardiovascular disease

Upcoming event

ISCC

15-18 October 2024 | Conference | Milan, Italy See all

Related Content

Finance

AbbVie completes acquisition of Cerevel Therapeutics

AbbVie now owns Cerevel's clinical-stage therapeutic pipeline for the treatment of Parkinson's, schizophrenia and MDD
Ingredients

Therapeutic: lutikizumab for hidradenitis suppurativa

Hidradenitis suppurativa (HS) — also known as acne inversa — is a chronic, recurrent and progressive inflammatory disease that leads to irreversible skin damage and disability
Ingredients

Therapeutic: atogepant for migraine

Migraine is thought to affect more than a billion people around the world and can have a significant impact on quality of life
Research & Development

AbbVie strengthen’s neuroscience portfolio with acquisition

Syndesi Therapeutics’ lead molecule, SDI-118, is a small molecule currently in Phase Ib studies, which is being evaluated to target nerve terminals to enhance synaptic efficiency
Regulatory

AbbVie and Eisai launch online Humira support tool service

The free-of-charge service assists patients on Humira therapy by delivering support tools to their home or other requested location
Manufacturing

CMC strategies for the acceleration of commercial-ready ADC manufacturing

The potential for antibody-drug conjugate (ADC) programmes to accelerate from early to late stage clinical development highlights the need to establish commercial launch-ready manufacturing early and efficiently, reports Courtney Morgret, Senior Scientist, Manufacturing Sciences, AbbVie
Media

GlobalData publishes analysis of top 25 global pharma companies

The data and analytics company has tracked the market cap performance of the top 25 pharma companies for the quarter ending 31 March, 2018 compared to 2017 revealing a number of interesting insights
Subscribe now